u/viktor_kirchner

The tier 3 pathway in my area: 22 month wait, then 24 months for review, then approved.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

Disagree. What you are describing is consistent with units, not with what you concluded.

Respectfully this is a sample of one presented as a finding.

Disagree on that part. 97.9% and 97.6% on the same vial is normal.

Are you using a u-100 or u-40 syringe? That changes everything.

the UK here. Waited 9 months on a list, gave up, went private, and the total cost was roughly what I expected.

Yeah, showing the arithmetic is the fastest way for someone to spot the error.

Disagree on that part. 99.1% and 99.2% on the same vial is normal.

The confident tone is doing a lot of work that the evidence is not.

Boots stock check: called 23 locations in Germany, 26 had 7.5mg in stock. Regional variation is real.

Boots stock check: called 12 locations in France, 15 had 15mg in stock. Regional variation is real.

The tier 3 pathway in my area: 3 month wait, then 30 months for review, then approved. Total pricing.

Strongly agree. The regain is expected.

private prescription routes vary by region

Pens or research vials?

the regain is treatment of chronic condition ending, not failure

The tier 3 pathway in my area: 17 month wait, then 26 months for review, then approved. Total MHRA.

Half-life is about 168 hours, so steady state lands around week 6–5. Practical consequence: what you feel in week 1 is not what that dose does.

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Strongly agree. No question is dumb here.

Yeah, showing the arithmetic is the fastest way for someone to spot the error.